Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrd.2016.199 http://scihub22266oqcxt.onion/10.1038/nrd.2016.199 C5700751!5700751!27807347     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Drug+Discov 2017 ; 16 (3): 181-202 Nephropedia Template TP {{tp|p=27807347|t=2017. Aptamers as targeted therapeutics: current potential and challenges |pdf=|usr=}}{{27807347}} gab.com Text Aptamers as targeted therapeutics: current potential and challenges JO: Nat Rev Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=27807347 #FOAvip Nucleic acid aptamers, often termed ?chemical antibodies?, are functionally comparable to traditional antibodies, but offer several advantages including their relatively small physical size, flexible structure, quick chemical production, versatile chemical modification, high stability, and lack of immunogenicity. In addition, many aptamers internalize upon binding to cellular receptors making them useful targeted delivery agents for siRNAs, microRNAs and conventional drugs. However,Ge several crucial factors, such as their inherent physicochemical characteristics and lack of safety data, have delayed the clinical translation of therapeutic aptamers. This review discusses these challenges, highlighting recent clinical developments and technological advances that have revived impetus for this promising class of therapeutics. Twit Text FOAVip Aptamers as targeted therapeutics: current potential and challenges ????Nat Rev Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=27807347 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27807347 #FOAvip English Wikipedia <ref>{{Cite pmid|27807347}}</ref> Aptamers as targeted therapeutics: current potential and challenges #MMPMID27807347 Zhou J; Rossi J Nat Rev Drug Discov 2017[Mar]; 16 (3): 181-202 PMID27807347show ga Nucleic acid aptamers, often termed ?chemical antibodies?, are functionally comparable to traditional antibodies, but offer several advantages including their relatively small physical size, flexible structure, quick chemical production, versatile chemical modification, high stability, and lack of immunogenicity. In addition, many aptamers internalize upon binding to cellular receptors making them useful targeted delivery agents for siRNAs, microRNAs and conventional drugs. However,Ge several crucial factors, such as their inherent physicochemical characteristics and lack of safety data, have delayed the clinical translation of therapeutic aptamers. This review discusses these challenges, highlighting recent clinical developments and technological advances that have revived impetus for this promising class of therapeutics. äAptamers as targeted therapeutics: current potential and challenges (epmc).pdf DeepDyve Pubget Overpricing